SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10821)3/4/2004 3:22:39 PM
From: Biomaven  Respond to of 52153
 
And co-incidentally Erik just posted a very recent abstract on Irofulven:

Message 19876325

I took a quick look at the full text. The synergistic effect wasn't there but not all that dramatic. Irofulven monotherapy at a high enough dose still performs very strongly in this tough prostate cancer model.

There's a more general question though. At some point we are going to see the "kinder gentler" chemo treatments gradually taking over from the cytotoxic drugs. Perhaps KOSN's epo D will be the apotheosis of the "old" drugs.

Be interesting to plot a graph of the "new" chemo drugs vs. the old. In dollar terms I wouldn't be surprised if the graphs aren't just about to cross (think Avastin and Erbitux to add to Rituxan) vs. Taxol and others going off patent.

Peter



To: Biomaven who wrote (10821)3/4/2004 4:05:32 PM
From: seminole  Read Replies (1) | Respond to of 52153
 
The animal model makes drug delivery nearly equal for any type of human tumor. The variability of drug transport, depending upon tumor type and location in humans, has limited the match with the animal model.

The literature, animal models and synergy studies point to expensive and large patient number studies of lung and breast. Apparently clinical data, cost and time efficient choices have lead to pancreatic and prostate study selection.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News